NCT02595372View on ClinicalTrials.gov

Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 12, 2015

Primary Completion Date

November 21, 2019

Study Completion Date

March 1, 2021

Conditions
Cancer of the Breast
Interventions
DRUG

Omeprazole

Trial Locations (9)

20007

Georgetown University, Washington D.C.

20010

Washington Hospital, Washington D.C.

21237

Franklin Square Medical Center, Baltimore

27157

Wake Forest Baptist Health, Winston-Salem

43210

Ohio State University, Columbus

46032

Indiana University Health North Hospital, Carmel

46202

Indiana University Health Hospital, Indianapolis

Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis

46290

Spring Mill Medical Center, Indianapolis

All Listed Sponsors
lead

Kathy Miller

OTHER

NCT02595372 - Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy | Biotech Hunter | Biotech Hunter